b 1287 profile

ID Source	ID
PubMed CID	6450173
CHEMBL ID	3301672
CHEBI ID	46692
MeSH ID	M0297733

Synonym
eritoran sodium
fuo195tc7o ,
e 5564
eritoran tetrasodium [usan]
unii-fuo195tc7o
b1287 saccharide
eritoran tetrasodium
e-5564
b-1287 ,
185954-98-7
D04043
e5564
eritoran tetrasodium (usan)
tetrasodium 3-o-decyl-2-deoxy-6-o-{2-deoxy-3-o-[(3r)-3-methoxydecyl]-6-o-methyl-2-[(11z)-octadec-11-enoylamino]-4-o-phosphonato-beta-d-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-o-phosphonato-alpha-d-glucopyranose
CHEBI:46692 ,
alpha-d-glucopyranose, 3-o-decyl-2-deoxy-6-o-(2-deoxy-3-o-((3r)-3-methoxydecyl)-6-o-methyl-2-(((11z)-1-oxo-11-octadecenyl)amino)-4-o-phosphono-beta-d-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-, 1-(dihydrogen phosphate), tetrasodium salt
3-o-decyl-2-deoxy-6-o-(2-deoxy-3-o-((3r)-3-methoxydecyl)-6-o-methyl-2-((11z)-octadec-11-enoylamino)-4-o-phosphonato-beta-d-glucopyranosyl)-2-((3-oxotetradecanoyl)amino)-alpha-d-glucopyranosyl tetrasodium phosphate
alpha-d-glucopyranose, 3-o-decyl-2-deoxy-6-o-(2-deoxy-3-o-((3r)-3-methoxydecyl)-6-o-methyl-2-(((11z)-1-oxo-11-octadecenyl)amino)-4-o-phosphono-beta-d-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-,1-(dihydrogen phosphate), tetrasodium salt
b1287 ,
tetrasodium [(2r,3r,4r,5s,6r)-4-decoxy-5-hydroxy-6-[[(2r,3r,4r,5s,6r)-4-[(3r)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(z)-octadec-11-enoyl]amino]-5-phosphonatooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] phosphate
.alpha.-d-glucopyranose, 3-o-decyl-2-deoxy-6-o-(2-deoxy-3-o-((3r)-3-methoxydecyl)-6-o-methyl-2-(((11z)-1-oxo-11-octadecenyl)amino)-4-o-phosphono-.beta.-d-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-, 1-(dihydrogen phosphate), tetrasodium salt
3-o-decyl-2-deoxy-6-o-(2-deoxy-3-o-((3r)-3-methoxydecyl)-6-o-methyl-2-((11z)-octadec-11-enoylamino)-4-o-phosphonato-.beta.-d-glucopyranosyl)-2-((3-oxotetradecanoyl)amino)-.alpha.-d-glucopyranosyl tetrasodium phosphate
eritoran tetrasodium salt
eritoran tetrasodium [who-dd]
1029325-41-4
eritoran tetrasodium salt [mi]
eritoran sodium [jan]
CHEMBL3301672
185954-98-7 (tetrasodium)
Q27120680
EX-A5459
tetrasodium;[(2r,3r,4r,5s,6r)-4-decoxy-5-hydroxy-6-[[(2r,3r,4r,5s,6r)-4-[(3r)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(z)-octadec-11-enoyl]amino]-5-phosphonatooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] phosphate

Class	Description
organic sodium salt

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (2.56)	18.2507
2000's	23 (58.97)	29.6817
2010's	15 (38.46)	24.3611
2020's	0 (0.00)	2.80

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (15.38%)	5.53%
Reviews	2 (5.13%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (79.49%)	84.16%

Substance	Classes	Roles	Relationship Strength
meclofenamate sodium anhydrous	organic sodium salt		low
4-phenylbutyric acid, sodium salt	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector; neuroprotective agent; orphan drug; prodrug	low
sodium citrate, anhydrous	organic sodium salt	anticoagulant; flavouring agent	low
sulfobromophthalein sodium	organic sodium salt	dye	low
suramin sodium	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug	low
evans blue	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent	low
sodium carbonate	carbonate salt; organic sodium salt		low
eosine yellowish-(ys)	organic sodium salt; organobromine compound	fluorochrome; histological dye	low
fast green fcf	organic sodium salt	fluorochrome; food colouring; histological dye	low
dexamethasone sodium phosphate	organic sodium salt	glucocorticoid receptor agonist	low
red 2g	organic sodium salt	histological dye	low
biebrich scarlet	organic sodium salt	histological dye	low
chromotrope 2r	organic sodium salt	histological dye	low
carbenicillin disodium	organic sodium salt		low
light green sf	organic sodium salt	histological dye	low
brilliant crocein	organic sodium salt	histological dye	low
etidronate disodium	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator	low
sytron	iron chelate; organic sodium salt		low
cromolyn sodium	organic sodium salt	anti-asthmatic drug; drug allergen	low
clodronate disodium	one-carbon compound; organic sodium salt	bone density conservation agent	low
foscarnet sodium	one-carbon compound; organic sodium salt	antiviral drug	low
pyranine	organic sodium salt	fluorochrome	low
betamethasone sodium phosphate	organic sodium salt; tertiary alpha-hydroxy ketone		low
c.i. direct red 80	organic sodium salt	fluorochrome; histological dye	low
disodium alpha-sulfobenzylpenicillin	organic sodium salt		low
estramustine phosphate sodium	organic sodium salt		low
sodium thiocyanate	organic sodium salt		low
sodium bicarbonate	one-carbon compound; organic sodium salt	antacid; food anticaking agent	low
sodium acetate, anhydrous	organic sodium salt	NMR chemical shift reference compound	low
sodium benzoate	organic sodium salt	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite	low
dipyrone	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug	low
formic acid, sodium salt	organic sodium salt	astringent; buffer	low
sodium propionate	organic sodium salt	antifungal drug; food preservative	low
ponceau s	organic sodium salt; organosulfonate salt	fluorochrome; histological dye	low
sodium ethoxide	organic sodium salt	nucleophilic reagent	low
nabam	dithiocarbamate salt; organic sodium salt	antifungal agrochemical	low
sodium dodecyl sulfate	organic sodium salt	detergent; protein denaturant	low
chloramine-t	organic sodium salt	allergen; antifouling biocide; disinfectant	low
primuline	organic sodium salt; organosulfonate salt	fluorochrome; histological dye	low
metanil yellow	organic sodium salt	histological dye	low
alizarin red s	organic sodium salt; organosulfonate salt	histological dye	low
diclofenac sodium	organic sodium salt		low
sodium butyrate	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector	low
sulfacetamide sodium	hydrate; organic sodium salt	antiinfective agent; antimicrobial agent; EC 2.5.1.15 (dihydropteroate synthase) inhibitor	low
lasalocid sodium	benzoates; organic sodium salt	coccidiostat; ionophore	low
lissamine rhodamine b	organic sodium salt	fluorescent probe; fluorochrome; histological dye	low
cefotaxime sodium	organic sodium salt		low
l 749345	organic sodium salt	antibacterial drug	low
thiopental sodium	organic sodium salt	intravenous anaesthetic	low
eosine i bluish	organic sodium salt	fluorescent dye; histological dye	low
rabeprazole sodium	organic sodium salt		low
pantoprazole sodium	organic sodium salt	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	low
azocarmine g	organic sodium salt	histological dye	low
pravastatin sodium	organic sodium salt; statin (semi-synthetic)	anticholesteremic drug	low
valproate sodium	organic sodium salt	geroprotector	low
tazobactam sodium	organic sodium salt	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor	low
cilastatin sodium	organic sodium salt	EC 3.4.13.19 (membrane dipeptidase) inhibitor; protease inhibitor	low
beraprost sodium	organic sodium salt	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent	low
tofisopam	organic sodium salt	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
azuletil sodium	organic sodium salt; organosulfonate salt	anti-ulcer drug; thromboxane A2 antagonist	low
brequinar sodium	organic sodium salt	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor	low
sri 62320	organic sodium salt; statin (synthetic)		low
methylprednisolone suleptanate	organic sodium salt	anti-asthmatic drug; anti-inflammatory agent; glucocorticoid receptor agonist; prodrug	low
ampicillin sodium	organic sodium salt		low
cerivastatin sodium	organic sodium salt; statin (synthetic)		low
montelukast sodium	organic sodium salt		low
cyanotriphenylborate	organic sodium salt; tetraorganoborate salt		low
thiopental sodium	organic sodium salt	intravenous anaesthetic	low
ahr 5850	organic sodium salt	cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor	low
cefamandole nafate	organic sodium salt	antibacterial drug; prodrug	low
cytomel	organic sodium salt		low
letter	organic sodium salt		low
sodium lactate	lactate salt; organic sodium salt	food acidity regulator; food preservative	low
cefmetazole sodium	organic sodium salt	antimicrobial agent	low
piperacillin sodium	organic sodium salt		low
methicillin sodium	organic sodium salt		low
dicloxacillin sodium	organic sodium salt		low
nafcillin sodium	organic sodium salt		low
oxacillin sodium	organic sodium salt		low
sodium cholate	cholate salt; organic sodium salt		low
penicillin g sodium	organic sodium salt		low
cefamandole nafate	organic sodium salt	antibacterial drug	low
sodium diatrizoate	organic sodium salt; organoiodine compound	radioopaque medium	low
docusate sodium	organic sodium salt		low
phenobarbital sodium	barbiturates; organic sodium salt		low
cephapirin sodium	cephalosporin; organic sodium salt	antibacterial drug	low
cloxacillin sodium	organic sodium salt		low
sodium cephalothin	organic sodium salt		low
cefazolin sodium	organic sodium salt		low
tolmetin sodium	hydrate; organic sodium salt	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug	low
nuclear fast red	organic sodium salt	fluorochrome; histological dye	low
fractals	organic sodium salt; statin (synthetic)		low
prednisolone sodium succinate	organic sodium salt	anti-inflammatory drug	low
naproxen sodium	organic sodium salt	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
alendronate sodium	hydrate; organic sodium salt	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor	low
azlocillin sodium	organic sodium salt		low
nafcillin sodium	hydrate; organic sodium salt		low
nxl 104	organic sodium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor	low
methampicillin, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))-isomer	organic sodium salt		low
ssr128129e	organic sodium salt	antineoplastic agent; fibroblast growth factor receptor antagonist	low
8-bromocyclic gmp, sodium salt	organic sodium salt	muscle relaxant; protein kinase G agonist	low
dy-676	organic sodium salt	fluorochrome	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's
chlorpromazine	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug	2000	2000	24.0	low	0	1	0	0
fluphenazine	1	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug	2000	2000	24.0	low	0	1	0	0
lidocaine	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic	2000	2000	24.0	low	0	1	0	0
s-methylisothiopseudouronium	1			2006	2006	18.0	low	0	0	1	0
trifluoperazine	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug	2000	2000	24.0	low	0	1	0	0
acetylcysteine	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2014	2014	10.0	low	0	0	0	1
manganese	1	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient	2004	2004	20.0	low	0	0	1	0
acetylglucosamine	1	N-acetyl-D-glucosamine	epitope	2013	2013	11.0	low	0	0	0	1
galactosamine	2	D-galactosamine; primary amino compound	toxin	2009	2010	14.5	low	0	0	2	0
isothiuronium	1			2006	2006	18.0	low	0	0	1	0
glucosamine	1	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite	2018	2018	6.0	low	0	0	0	1
bilirubin	2	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite	2009	2010	14.5	low	0	0	2	0
e 5531	1			2000	2000	24.0	low	0	1	0	0
mocetinostat	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	2014	2014	10.0	low	0	0	0	1
lipid a	39	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite	1999	2019	16.2	high	6	2	25	12
ro13-9904	1			2014	2014	10.0	low	0	0	0	1
crx-526	1			2018	2018	6.0	medium	0	0	0	1

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's
Acute Hepatic Failure	0	2	2009	2010	14.5	low	0	0	2	0
Acute Lung Injury	0	1	2014	2014	10.0	low	0	0	0	1
Acute Respiratory Distress Syndrome	0	1	2018	2018	6.0	low	0	0	0	1
Airflow Obstruction, Chronic	0	1	2018	2018	6.0	low	0	0	0	1
Airway Hyper-Responsiveness	0	1	2005	2005	19.0	low	0	0	1	0
Asthma	0	1	2018	2018	6.0	low	0	0	0	1
Asthma, Bronchial	0	1	2018	2018	6.0	low	0	0	0	1
Bacterial Disease	0	1	2010	2010	14.0	low	1	0	1	0
Bacterial Infections	0	1	2010	2010	14.0	low	1	0	1	0
Bacterial Infections, Gram-Negative	0	1	2006	2006	18.0	low	0	0	1	0
Blood Poisoning	0	6	2004	2014	15.7	low	2	0	5	1
Body Weight	0	1	2015	2015	9.0	low	0	0	0	1
Brain Ischemia	0	1	2019	2019	5.0	low	0	0	0	1
Cardiomyopathies	0	1	2006	2006	18.0	low	0	0	1	0
Cardiomyopathies, Primary	0	1	2006	2006	18.0	low	0	0	1	0
Cerebral Ischemia	0	1	2019	2019	5.0	low	0	0	0	1
Cirrhosis, Liver	0	1	2003	2003	21.0	low	1	0	1	0
Complication, Postoperative	0	1	2007	2007	17.0	low	1	0	1	0
Critical Illness	0	2	2010	2010	14.0	low	2	0	2	0
Diabetes Mellitus	0	1	2018	2018	6.0	low	0	0	0	1
Disease Models, Animal	0	8	2002	2019	13.9	low	0	0	5	3
E coli Infections	0	2	2006	2014	14.0	low	0	0	1	1
Endotoxemia	0	5	2003	2008	19.0	low	2	0	5	0
Endotoxin Shock	0	2	2003	2004	20.5	low	0	0	2	0
Enterocolitis, Necrotizing	0	1	2013	2013	11.0	low	0	0	0	1
Escherichia coli Infections	0	2	2006	2014	14.0	low	0	0	1	1
Experimental Lung Inflammation	0	1	2005	2005	19.0	low	0	0	1	0
Gram-Negative Bacterial Infections	0	1	2006	2006	18.0	low	0	0	1	0
Grippe	0	1	2014	2014	10.0	low	0	0	0	1
Hemorrhagic Shock	0	1	2014	2014	10.0	low	0	0	0	1
Infections, Orthomyxoviridae	0	1	2014	2014	10.0	low	0	0	0	1
Infections, Pseudomonas	0	1	2013	2013	11.0	low	0	0	0	1
Infections, Respiratory Syncytial Virus	0	1	2012	2012	12.0	low	0	0	0	1
Inflammation	0	4	2001	2018	12.8	low	0	0	1	3
Influenza, Human	0	1	2014	2014	10.0	low	0	0	0	1
Injuries, Soft Tissue	0	1	2014	2014	10.0	low	0	0	0	1
Injury, Ischemia-Reperfusion	0	1	2012	2012	12.0	low	0	0	0	1
Innate Inflammatory Response	0	4	2001	2018	12.8	low	0	0	1	3
Insulin Resistance	0	1	2015	2015	9.0	low	0	0	0	1
Insulin Sensitivity	0	1	2015	2015	9.0	low	0	0	0	1
Ischemia	0	1	2012	2012	12.0	low	0	0	0	1
Liver Cirrhosis	0	1	2003	2003	21.0	low	1	0	1	0
Liver Failure, Acute	0	2	2009	2010	14.5	low	0	0	2	0
Lung Injury, Acute	0	1	2014	2014	10.0	low	0	0	0	1
Necrotizing Enterocolitis	0	1	2013	2013	11.0	low	0	0	0	1
Obesity	0	1	2015	2015	9.0	low	0	0	0	1
Orthomyxoviridae Infections	0	1	2014	2014	10.0	low	0	0	0	1
Periphlebitis	0	1	2008	2008	16.0	low	0	0	1	0
Peritonitis	0	1	2014	2014	10.0	low	0	0	0	1
Phlebitis	0	1	2008	2008	16.0	low	0	0	1	0
Pneumonia	0	1	2005	2005	19.0	low	0	0	1	0
Postoperative Complications	0	1	2007	2007	17.0	low	1	0	1	0
Primary Peritonitis	0	1	2014	2014	10.0	low	0	0	0	1
Pseudomonas Infections	0	1	2013	2013	11.0	low	0	0	0	1
Pulmonary Disease, Chronic Obstructive	0	1	2018	2018	6.0	low	0	0	0	1
Reperfusion Injury	0	1	2012	2012	12.0	low	0	0	0	1
Respiratory Distress Syndrome	0	1	2018	2018	6.0	low	0	0	0	1
Respiratory Syncytial Virus Infections	0	1	2012	2012	12.0	low	0	0	0	1
Sensitivity and Specificity	0	1	1999	1999	25.0	low	0	1	0	0
Sepsis	1	6	2004	2014	15.7	low	2	0	5	1
Shock, Septic	0	2	2003	2004	20.5	low	0	0	2	0
Tachyarrhythmia	0	1	2004	2004	20.0	low	1	0	1	0
Tachycardia	0	1	2004	2004	20.0	low	1	0	1	0

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models.
British journal of pharmacology, , Volume: 176, Issue:15, 2019

Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation.
Biomaterials, , Volume: 159, 2018

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 63, Issue:11, 2014

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.
The Journal of infectious diseases, , Mar-01, Volume: 193, Issue:5, 2006

Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation.
Biomaterials, , Volume: 159, 2018

Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the Toll-like receptor 4 signaling pathway.
Infection and immunity, , Volume: 81, Issue:12, 2013

Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors.
PloS one, , Volume: 8, Issue:6, 2013

The extra domain A of fibronectin activates Toll-like receptor 4.
The Journal of biological chemistry, , Mar-30, Volume: 276, Issue:13, 2001

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

Pharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in Rats.
PloS one, , Volume: 10, Issue:7, 2015

[The role of toll like receptor-4 signal pathways activation in ischemia-reperfusion injury of island skin flap].
Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, , Volume: 28, Issue:6, 2012

Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function.
Journal of clinical pharmacology, , Volume: 43, Issue:12, 2003

Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia.
Shock (Augusta, Ga.), , Volume: 25, Issue:1, 2006

Pharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in Rats.
PloS one, , Volume: 10, Issue:7, 2015

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 63, Issue:11, 2014

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Innate immunity, , Volume: 14, Issue:6, 2008

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
American journal of physiology. Lung cellular and molecular physiology, , Volume: 289, Issue:2, 2005

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
Anesthesia and analgesia, , Volume: 104, Issue:2, 2007

Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the Toll-like receptor 4 signaling pathway.
Infection and immunity, , Volume: 81, Issue:12, 2013

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications, , Dec-24, Volume: 736, Issue:1-2, 1999

LPS binding protein does not participate in the pharmacokinetics of E5564.
Journal of endotoxin research, , Volume: 10, Issue:3, 2004

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
The Journal of pharmacology and experimental therapeutics, , Volume: 304, Issue:3, 2003

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
The Journal of pharmacology and experimental therapeutics, , Volume: 308, Issue:1, 2004

[The role of toll like receptor-4 signal pathways activation in ischemia-reperfusion injury of island skin flap].
Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, , Volume: 28, Issue:6, 2012

Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia.
Shock (Augusta, Ga.), , Volume: 25, Issue:1, 2006

Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
Journal of gastroenterology and hepatology, , Volume: 25, Issue:5, 2010

Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury.
Journal of gastroenterology and hepatology, , Volume: 24, Issue:6, 2009

Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.
mBio, , Volume: 3, Issue:4, 2012

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 63, Issue:11, 2014

Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Syntheses of glucose analogues of E5564 as a highly potent anti-sepsis drug candidate.
Bioorganic & medicinal chemistry, , May-01, Volume: 14, Issue:9, 2006

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.
The Journal of infectious diseases, , Mar-01, Volume: 193, Issue:5, 2006

Drug evaluation: E-5564.
IDrugs : the investigational drugs journal, , Volume: 7, Issue:6, 2004

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Innate immunity, , Volume: 14, Issue:6, 2008

Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia.
Shock (Augusta, Ga.), , Volume: 25, Issue:1, 2006

Drug evaluation: E-5564.
IDrugs : the investigational drugs journal, , Volume: 7, Issue:6, 2004

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
The Journal of pharmacology and experimental therapeutics, , Volume: 308, Issue:1, 2004

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
The Journal of infectious diseases, , Feb-15, Volume: 187, Issue:4, 2003

Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors.
PloS one, , Volume: 8, Issue:6, 2013

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

Toll-like receptor 4 plays a central role in cardiac dysfunction during trauma hemorrhage shock.
Shock (Augusta, Ga.), , Volume: 42, Issue:1, 2014

Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.
mBio, , Volume: 3, Issue:4, 2012

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 63, Issue:11, 2014

Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Syntheses of glucose analogues of E5564 as a highly potent anti-sepsis drug candidate.
Bioorganic & medicinal chemistry, , May-01, Volume: 14, Issue:9, 2006

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.
The Journal of infectious diseases, , Mar-01, Volume: 193, Issue:5, 2006

Drug evaluation: E-5564.
IDrugs : the investigational drugs journal, , Volume: 7, Issue:6, 2004

Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors.
PloS one, , Volume: 8, Issue:6, 2013

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Pharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in Rats.
PloS one, , Volume: 10, Issue:7, 2015

Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models.
British journal of pharmacology, , Volume: 176, Issue:15, 2019

Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models.
British journal of pharmacology, , Volume: 176, Issue:15, 2019

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
Journal of gastroenterology and hepatology, , Volume: 25, Issue:5, 2010

Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury.
Journal of gastroenterology and hepatology, , Volume: 24, Issue:6, 2009

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.
The Journal of infectious diseases, , Mar-01, Volume: 193, Issue:5, 2006

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
The Journal of pharmacology and experimental therapeutics, , Volume: 304, Issue:3, 2003

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
Journal of endotoxin research, , Volume: 8, Issue:6, 2002

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 63, Issue:11, 2014

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.
The Journal of infectious diseases, , Mar-01, Volume: 193, Issue:5, 2006

Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation.
Biomaterials, , Volume: 159, 2018

Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors.
PloS one, , Volume: 8, Issue:6, 2013

Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the Toll-like receptor 4 signaling pathway.
Infection and immunity, , Volume: 81, Issue:12, 2013

The extra domain A of fibronectin activates Toll-like receptor 4.
The Journal of biological chemistry, , Mar-30, Volume: 276, Issue:13, 2001

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

Pharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in Rats.
PloS one, , Volume: 10, Issue:7, 2015

Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function.
Journal of clinical pharmacology, , Volume: 43, Issue:12, 2003

Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia.
Shock (Augusta, Ga.), , Volume: 25, Issue:1, 2006

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.
International immunopharmacology, , Volume: 22, Issue:1, 2014

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 63, Issue:11, 2014

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Innate immunity, , Volume: 14, Issue:6, 2008

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
American journal of physiology. Lung cellular and molecular physiology, , Volume: 289, Issue:2, 2005

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
Anesthesia and analgesia, , Volume: 104, Issue:2, 2007

Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the Toll-like receptor 4 signaling pathway.
Infection and immunity, , Volume: 81, Issue:12, 2013

Insights into endotoxin-mediated lung inflammation and future treatment strategies.
Expert review of respiratory medicine, , Volume: 12, Issue:11, 2018

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
American journal of physiology. Lung cellular and molecular physiology, , Volume: 289, Issue:2, 2005

Toll-like receptor 4 plays a central role in cardiac dysfunction during trauma hemorrhage shock.
Shock (Augusta, Ga.), , Volume: 42, Issue:1, 2014

LPS binding protein does not participate in the pharmacokinetics of E5564.
Journal of endotoxin research, , Volume: 10, Issue:3, 2004

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
The Journal of pharmacology and experimental therapeutics, , Volume: 304, Issue:3, 2003

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
The Journal of pharmacology and experimental therapeutics, , Volume: 308, Issue:1, 2004

[The role of toll like receptor-4 signal pathways activation in ischemia-reperfusion injury of island skin flap].
Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, , Volume: 28, Issue:6, 2012

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
Critical care medicine, , Volume: 38, Issue:1, 2010

Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia.
Shock (Augusta, Ga.), , Volume: 25, Issue:1, 2006

Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
Journal of gastroenterology and hepatology, , Volume: 25, Issue:5, 2010

Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury.
Journal of gastroenterology and hepatology, , Volume: 24, Issue:6, 2009

b 1287

Description

Cross-References

Synonyms (32)

Drug Classes (1)

Research

Studies (39)

Study Types

Safety/Toxicity (1)

Pharmacokinetics (6)

Dosage (6)

Article	Year
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. Innate immunity, , Volume: 14, Issue:6	2008
Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. The Journal of infectious diseases, , Mar-01, Volume: 193, Issue:5	2006
Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. American journal of physiology. Lung cellular and molecular physiology, , Volume: 289, Issue:2	2005
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]. The Journal of pharmacology and experimental therapeutics, , Volume: 308, Issue:1	2004
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. Journal of endotoxin research, , Volume: 8, Issue:6	2002
Disposition of a synthetic analogue of lipid A (E5564) in rats. Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 33, Issue:3	2003

b 1287

Description

Cross-References

Synonyms (32)

Drug Classes (1)

Research

Studies (39)

Study Types

Related Drugs (116)

Drugs in this Class (99)

Drugs Researched Together (17)

Related Conditions (63)

Safety/Toxicity (1)

Pharmacokinetics (6)

Dosage (6)